Pelican Therapeutics
LinkedIn
Heat Biologics, Inc.
Home
About
Overview
Management Team
Board of Directors
Scientific Advisory Board
Technology
Overview
ImPACT
ComPACT
Pelican’s PTX-35 Co-stimulatory Antibody
Scientific Publications
Product Pipeline
Overview
HS-110
HS-130
PTX-35
Expanded Access
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Corporate Presentation
News & Media
News Releases
Events
Careers
Contact
Pelican Therapeutics
News / Events
Investors
Investors
Overview
News / Events
Overview
Press Releases
IR Calendar
Email Alerts
Company Info
Overview
Presentations
Management Team
Contacts
FAQ
Financial Info
Overview
Balance Sheet
Income Statement
Cash Flow
Financial Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Corporate Presentation
News / Events
Overview
Press Releases
IR Calendar
Email Alerts
Recent News
View All News
Heat Biologics, Inc. Prices $7,000,000 Public Offering
January 16, 2020
Heat Biologics Announces First Patient Dosed in the First Phase 1 Trial of HS-130
December 16, 2019
View All News
Email Alerts
Sign up for email alerts for Press Releases & SEC Filings
Sign Up
Email Alerts
Tear Sheet
Contacts
RSS News Feed
